Watching NGM Biopharmaceuticals Shares; Traders Circulate Document Titled ‘Explorer Series 2: Myeloid Reprogramming and Stromal Checkpoint Programs’
https://docs.publicnow.com/viewDoc?hash_primary=814442E35D1F91F75FCB342314ECD51FBDA8AF93
55 Biggest Movers From Friday
Gainers
Takung Art Co., Ltd. (NASDAQ: TKAT) surged 61.8% to close at $3.64 on Friday.
NGM Bio Announces Initiation Of Phase 1/1b Clinical Trial Of NGM831 For The Treatment of Patients With Advanced Solid Tumors
Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and expected to
NGM Biopharmaceuticals’s Return On Capital Employed Overview
According to Benzinga Pro data, during Q4, NGM Biopharmaceuticals (NASDAQ:NGM) posted sales of $20.96 million. Earnings were up 5.65%, but NGM Biopharmaceuticals still reported an overall loss of $27.23 million.
Raymond James Maintains Strong Buy on NGM Biopharmaceuticals, Raises Price Target to $42
Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Strong Buy and raises the price target from $39 to $42.
10 Biggest Price Target Changes For Friday
UBS cut FedEx Corporation (NYSE: FDX) price target from $397 to $380. FedEx shares fell 0.2% to $258.00 in pre-market trading.
BMO Capital Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $35
BMO Capital analyst Matthew Luchini maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $29 to $35.